demonstrated that in melanoma, colon and pancreatic cancers, blocking CDK1 expression reduced the phosphorylation, localisation and transcriptional activity of the pluripotency‐associated transcription factor SOX2, thereby inhibiting tumour initiation.26 This evidence concerns the gene SOX2 and pancreatic neoplasm.